Airfinity a finalist in British Data Awards 2025 for investigating surging diseases

Posted on Mar 20, 2025

Airfinity has been selected as a finalist for the British Data Awards 2025 in the Data Partnership of the Year category. We have been shortlisted for our work with Bloomberg News to investigate the global resurgence of infectious diseases following the pandemic. 

Our study, published in June 2024, revealed over 40 countries or territories have reported at least one infectious disease resurgence that’s 10-fold or more over their pre-pandemic baseline. The study has compiled data from over 60 organisations and public health agencies showing that the world is seeing a resurgence of at least 13 infectious diseases, with cases higher than before the pandemic in many regions. The findings highlighted three key drivers behind these outbreaks: falling vaccination rates, declining population immunity, and climate change disruptions.

This project aimed to address a major information gap in public health intelligence by assessing how infectious diseases rebounded after the disruptions caused by COVID-19. Surveillance reports typically focus on multiple diseases within a single country or a single disease across a region, often with limited time granularity. This project addressed that gap by delivering a comprehensive, near real-time, multi-disease global comparison—an innovative approach not previously attempted at this scale. 

The British Data Awards is an annual quest to discover and celebrate the UK’s data success stories.  The collaboration between Airfinity and Bloomberg News showcases the power of data-driven journalism in uncovering and contextualising global health trends and we’re delight the work is being recognised.

You can read the article on Bloomberg in this link and our interactive spike map here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022